参麦注射液联合综合心理干预在非小细胞肺癌化疗中_临床医学论文.docVIP

参麦注射液联合综合心理干预在非小细胞肺癌化疗中_临床医学论文 参麦注射液联合综合心理干预在非小细胞肺癌化疗中_临床医学论文 作者：倪秉强，张志红，伍美娟，花园春 【摘要】 ：［目的］观察参麦注射液（SMI）联合综合心理干预在晚期非小细胞肺癌（NSCLC）化疗中的使用价值。［方法］晚期NSCLC 79例，治疗组40例，采用常规化疗配合参麦注射液联合综合心理干预，并与单纯化疗的39例作对照，观察两组的体力状况、疗效、1年生存率、骨髓抑制情况等。［结果］治疗组和对照组的Karnofsky评分提高+稳定率为75.0%及46.2%、疗效稳定以上率（CR+PR+NC）为70.0%及46.2%,1年生存率为47.5%及25.6%。治疗组与对照 组的Ⅱ度以上的白细胞下降的发生率分别为32.5%及53.8%（P=0.032），Ⅱ度以上的血小板下降的发生率分别为30.0%及46.2%（P=0.032），之间的差异均有统计学意义。［结论］治疗组的Karnofsky评分、疗效稳定以上率、1年 生存率、骨髓抑制发生率均优于对照组，提示SMI及心理干预联合化疗治疗晚期NSCLC有增效减毒作用。 【关键词】 参麦注射液;非小细胞肺癌；综合心理干预; 　　Abstract：［Objective］To evaluate the efficacyof Shenmai injection combined with psychotherapy inchemotherapy of non［Method］79 cases of advanced non，40cases in observation group with Shenmai injectioncombined with chemotherapy and psychotherapy，39cases in control group with chemotherapy alone.TheKarnofsky scores，therapeutic efficacy，one yearsurvival rate and incidence of myelosuppressionwere evaluated.［Result］ The two groups weresignificantly different in Karnofsky scores，therapeutic efficacy and one year survival rate.Theimprovement and stability rate of Karnofsky scoresand that of therapeutic efficacy were 75.0% and70.0% in observation group，with 46.2% and 46.2% incontrol group，respectively.One year survival ratewas 47.5% in observation group and 25.6% in controlgroup，respectively.The incidence ofmyelosuppression had significant differences in thetwo groups，with grade 2～4 leucopenia 32.5% inobservation group and 53.8% in control group（P=0.032），with grade 2～3 thrombocytopenia 30.0%in observation group and 46.2% in control group（P=0.032）.［Conclusion］ Combination treatment inobservation group was superior to the treatment incontrol group，with a higher Karnofsky scores，moreeffective therapy，a higher one year survival rateand a lower incidence of myelosuppression.Thetreatment of Shenmai injection combind withchemotherapy could reduce toxicity and enhancetherapeutic efficacy.　　 　　Key words: Shenmai injection（SMI）;nonmotherapy 　　Ⅲb、Ⅳ期非小细胞肺癌（NSCLC）化疗的价值已得到肯定，但因其高